List of Excipients in Branded Drug FOLOTYN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Acrotech Biopharma Inc	FOLOTYN	pralatrexate	48818-001	HYDROCHLORIC ACID
Acrotech Biopharma Inc	FOLOTYN	pralatrexate	48818-001	SODIUM CHLORIDE
Acrotech Biopharma Inc	FOLOTYN	pralatrexate	48818-001	SODIUM HYDROXIDE
Acrotech Biopharma Inc	FOLOTYN	pralatrexate	48818-001	WATER

FOLOTYN Excipient Strategy and Commercial Opportunities

Last updated: August 26, 2026

FOLOTYN, the brand name for pralatrexate injection, has a low-complexity excipient profile and a relatively limited formulation moat. The product is a ready-to-use intravenous concentrate containing pralatrexate, sodium chloride, hydrochloric acid, and sodium hydroxide for pH adjustment. Its commercial protection depends more on regulatory know-how, oncology distribution, physician adoption, and supply reliability than on proprietary excipient technology.

The strongest excipient opportunities are incremental: ready-to-administer presentations, lower-waste vial configurations, improved stability, preservative-free packaging, and hospital-use formats that reduce preparation time. A competing injectable could likely reproduce the basic formulation without significant excipient-related patent risk, subject to pharmaceutical equivalence, stability, container-closure, sterility, and FDA approval requirements.

What excipients are used in FOLOTYN?

FOLOTYN is a sterile, preservative-free pralatrexate injection supplied as a 20 mg/mL concentrate for intravenous administration. The FDA prescribing information identifies sodium chloride as the principal inactive ingredient. Hydrochloric acid and sodium hydroxide are used to adjust pH.[1]

Product attribute	FOLOTYN specification
Active ingredient	Pralatrexate
Strength	20 mg/mL
Dosage form	Sterile intravenous injection concentrate
Route	Intravenous
Principal excipient	Sodium chloride
pH agents	Hydrochloric acid and sodium hydroxide
Preservatives	None identified in the FDA label
Packaging	Single-dose vial presentations
Storage	Refrigerated storage, protected from light
Administration	IV push over approximately 3 to 5 minutes
Indication	Relapsed or refractory peripheral T-cell lymphoma

The formulation is deliberately simple. Sodium chloride supports isotonicity, while acid and base adjustment controls pH. The label does not identify a complex buffer system, surfactant, cosolvent, antimicrobial preservative, or lyophilization aid.[1]

How does FOLOTYN’s excipient profile affect commercial strategy?

The simple formulation reduces manufacturing complexity but also limits formulation differentiation. A competitor would not need to replicate a sophisticated delivery platform. The principal technical barriers would be:

1. Demonstrating chemical and physical stability.
2. Matching the reference product’s strength and route.
3. Establishing sterility and container-closure integrity.
4. Showing compatibility with the vial, syringe, transfer device, and infusion equipment.
5. Supporting an ANDA or other FDA pathway with sufficient product-quality data.

The absence of a complex excipient system is commercially favorable for generic manufacturers. It reduces raw-material qualification requirements, simplifies scale-up, and lowers the risk that a formulation-specific patent blocks market entry.

For the branded product, the same simplicity creates an opportunity to shift value from formulation chemistry to workflow performance. A product that reduces pharmacy preparation, minimizes vial waste, improves dose measurement, or offers more convenient storage could obtain commercial differentiation even if its excipient composition remains conventional.

What formulation opportunities exist for FOLOTYN?

Ready-to-administer presentations

FOLOTYN is already supplied as an injection concentrate, but the product still requires dose calculation, vial selection, handling, and administration by oncology staff. A ready-to-administer syringe or small-volume infusion presentation could reduce pharmacy compounding steps.

Potential advantages include:

• Lower preparation labor.
• Fewer manipulation steps for a cytotoxic drug.
• Reduced dosing and transfer errors.
• Improved auditability in hospital pharmacies.
• Lower risk of residual drug loss from vial overfill or incomplete withdrawal.

The regulatory burden would include container-closure validation, extractables and leachables testing, dose uniformity, shipping qualification, and stability through the labeled use period.

Vial-size optimization

Pralatrexate dosing is based on body-surface area at 30 mg/m² once weekly for six doses in a seven-week cycle, subject to dose modifications.[1] This dosing model creates variable dose requirements across patients.

A two-size vial strategy can reduce discarded drug:

Presentation strategy	Commercial objective
One small vial	Lower acquisition cost for low-dose patients
One large vial	Better fit for high-dose patients
Small and large vial combination	Minimize residual waste across body-surface-area ranges
Unit-dose pharmacy pack	Improve inventory control and charge capture
Ready-to-administer syringe	Reduce compounding labor and handling

Vial configuration may produce a stronger hospital value proposition than a new excipient. The economic case depends on acquisition price, average patient dose, vial overfill, beyond-use time after opening, and the number of patients treated per preparation session.

Improved storage and handling

The labeled product requires refrigerated storage and protection from light.[1] A formulation or container-closure system that supports controlled room-temperature storage could reduce cold-chain costs and improve use in outpatient oncology clinics.

Potential approaches include:

• Higher-barrier primary packaging.
• Light-protective vial or overwrap systems.
• Stabilizing pH control.
• Reduced oxygen exposure.
• Improved stopper and seal configuration.
• Validated short-term excursions during transport.

A room-temperature presentation would require substantial stability evidence. It would also need to show that degradation products, visible and subvisible particles, potency, and sterility remain within specification.

Low-sorption and low-residual-volume systems

Because pralatrexate is administered at a relatively small volume, adsorption to syringes, transfer devices, or tubing could affect dose recovery. A low-sorption syringe or administration set could improve delivered-dose consistency.

This opportunity is more likely to support a device or combination-product strategy than a conventional excipient patent. A sponsor could seek protection around:

• Specific polymer or elastomer contact materials.
• Low-residual-volume connectors.
• Drug-compatible syringe components.
• Integrated transfer and administration systems.
• Validated hold times and dose-recovery parameters.

What patents protect FOLOTYN’s formulation?

The public FDA labeling identifies the formulation components but does not establish a broad, standalone excipient patent estate. The basic combination of pralatrexate, sodium chloride, and pH-adjusting agents is technically conventional and may be difficult to protect with broad claims.

Potentially protectable subject matter could include:

Patent strategy	Likely commercial value
Specific pH range	Moderate if linked to unexpected stability or impurity control
Defined degradation limits	Moderate, if tied to a distinctive formulation
Container-closure system	Moderate to high for a proprietary presentation
Ready-to-use syringe	High if it reduces preparation or waste
Low-sorption administration set	Moderate
Vial configuration	Usually limited unless linked to a device or manufacturing claim
Freeze-dried pralatrexate	Potentially high, but requires new formulation and reconstitution data
Novel excipient combination	Potentially high, but must show a meaningful technical advantage
Manufacturing process	Moderate if difficult to reproduce and supported by enforceable claims

A patent directed only to sodium chloride concentration or pH adjustment would face enablement, written-description, obviousness, and clinical relevance challenges unless the applicant could demonstrate an unexpected result. A stronger claim set would connect the formulation to a measurable benefit, such as substantially improved stability, lower impurity formation, improved recovery from administration devices, or reduced degradation during storage.

When did FOLOTYN lose orphan exclusivity?

The FDA approved FOLOTYN on September 24, 2009, under the accelerated approval pathway for relapsed or refractory peripheral T-cell lymphoma.[2] The product received orphan-drug exclusivity for the approved indication. The seven-year orphan exclusivity period therefore ran approximately through September 24, 2016, subject to the specific scope of the designation and approval.

Orphan exclusivity is separate from patent protection. It prevents FDA approval of the same drug for the same orphan indication by another sponsor during the exclusivity period, subject to statutory exceptions. It does not prevent all competing products or protect new formulations outside the exclusivity scope.

The current commercial risk is therefore primarily generic, formulation, manufacturing, and market-access risk rather than continuing orphan exclusivity.

What is the FDA and Orange Book status of FOLOTYN?

FOLOTYN was approved as an NDA product, NDA 022481, for a serious and rare hematologic malignancy.[1,2] The FDA label identifies pralatrexate injection as the approved product and provides the dosing, preparation, storage, and safety requirements for clinical use.

For commercial diligence, the relevant regulatory questions are:

• Whether the reference product is listed in the current Orange Book.
• Whether any patents or regulatory exclusivity codes remain listed.
• Whether an ANDA applicant can establish therapeutic equivalence to the injection.
• Whether the proposed generic matches the reference product’s strength, route, dosage form, and inactive ingredients.
• Whether the applicant must provide additional clinical or pharmacokinetic data because of formulation differences.

A simple injectable formulation generally supports an ANDA strategy if the proposed product can meet pharmaceutical-equivalence and bioequivalence requirements. A formulation with materially different excipients, packaging, concentration, or administration characteristics could create additional FDA review issues.

Are there Paragraph IV challenges to FOLOTYN?

A Paragraph IV challenge would be the expected route for an ANDA applicant seeking approval before expiration of any Orange Book-listed patents. The applicant would certify that listed patents are invalid, unenforceable, or will not be infringed.

The commercial importance of a Paragraph IV filing depends on four factors:

1. The number and scope of listed patents.
2. Whether the patents cover the active ingredient, formulation, method of use, or manufacturing process.
3. The timing of the ANDA filing.
4. The brand holder’s decision to file patent litigation within the statutory period.

A plain pralatrexate injection could face less formulation-related risk than a product with a complex delivery system. Method-of-use patents could remain relevant if they cover treatment of peripheral T-cell lymphoma, dosing schedules, patient selection, or use with folic acid and vitamin B12 supplementation.

The available product information does not establish a current, commercially material Paragraph IV litigation campaign involving FOLOTYN. Patent and litigation status should be assessed against the current FDA Orange Book and PACER records because these positions can change after label revisions, patent listings, or ANDA filings.

What method-of-use patents and clinical restrictions matter?

FOLOTYN treatment requires folic acid and vitamin B12 supplementation to reduce toxicity. The label recommends folic acid beginning 10 days before the first dose and continuing during treatment, along with vitamin B12 administration before treatment and at regular intervals.[1]

This creates limited commercial differentiation because the supplements are standard supportive-care products rather than proprietary FOLOTYN excipients. A sponsor could seek method-of-use protection around a particular patient population, dosing adjustment, sequencing strategy, or combination regimen, but broad claims would face prior-art and obviousness scrutiny.

The clinically relevant formulation constraints are more important than the supplement regimen:

• Pralatrexate is a cytotoxic antimetabolite.
• The product is administered intravenously.
• Dose reduction or interruption may be required for toxicity.
• Mucositis, thrombocytopenia, neutropenia, and anemia affect treatment continuity.
• Renal and hepatic status can affect patient selection and dose management.

A formulation that improves dose recovery or reduces administration errors could have clinical value without changing the active ingredient.

Which companies are commercializing or challenging FOLOTYN?

Allos Therapeutics originally developed FOLOTYN. Spectrum Pharmaceuticals acquired Allos in 2012. Acrotech Biopharma later acquired Spectrum’s U.S. commercial oncology portfolio, including FOLOTYN, along with other products.[3]

The competitive landscape includes:

• Acrotech as the U.S. branded commercial owner.
• Potential ANDA applicants seeking a pralatrexate injection.
• Competing treatments for relapsed or refractory peripheral T-cell lymphoma.
• Hospital pharmacies and specialty distributors that influence product selection.
• Alternative systemic therapies, including brentuximab vedotin for relevant CD30-positive disease and other lymphoma regimens.

The commercial market is narrow because FOLOTYN is used primarily in a relapsed or refractory disease setting. Its value is concentrated in specialized hematology-oncology centers, where physician familiarity, reimbursement, supply continuity, and treatment protocols can matter as much as the vial price.

How strong is the FOLOTYN patent estate?

The formulation estate appears weaker than the regulatory and commercial estate.

Protection category	Relative strength
Orphan-drug exclusivity	Expired for the original 2009 indication
Basic excipient formulation	Likely limited
Pralatrexate active-ingredient patents	Requires current patent-record verification
Method-of-use claims	Potentially relevant but indication-specific
Manufacturing claims	Possible source of residual protection
Container-closure and device claims	Opportunity for new product development
Trade secrets and process know-how	Potentially meaningful
Distribution and oncology relationships	Commercially important

A competitor’s most defensible position would likely come from a differentiated presentation, a manufacturing process with demonstrated superiority, or a device-enabled product rather than from a broad claim to the existing excipient composition.

What generic launch risks exist for FOLOTYN?

Generic entry could occur through several scenarios:

Conventional vial generic

This is the highest-probability competitive model. The applicant would reproduce the 20 mg/mL injectable presentation with a pharmaceutically equivalent excipient profile or a permitted equivalent.

Lower-waste vial strategy

A generic manufacturer could compete through multiple vial sizes, aggressive contracting, and hospital inventory economics. This could pressure the branded product even without a major formulation change.

Ready-to-administer product

A prefilled syringe or pharmacy-ready presentation could compete on labor savings and safety. FDA classification and product-specific requirements would depend on the design and the degree of difference from the reference injection.

505(b)(2) reformulation

A reformulated pralatrexate product with a new concentration, delivery system, storage profile, or route could use a 505(b)(2) pathway. This approach could support new exclusivity or patents but would carry greater development and regulatory cost than a conventional ANDA.

What licensing and partnering opportunities exist?

The strongest partnering opportunities are likely to involve delivery and hospital workflow rather than a new excipient alone.

Potential deal structures include:

Opportunity	Potential partner
Ready-to-administer syringe	Injectable specialist or combination-product company
Low-waste vial packaging	Contract manufacturer or oncology supplier
Room-temperature stability	Formulation-development company
Closed-system transfer device	Medical-device manufacturer
Regional commercialization	Specialty oncology distributor
Generic supply	ANDA holder or contract injectable manufacturer
New pralatrexate combination	Hematology-focused biotechnology company

A licensing package would be more attractive if it included validated stability data, a scalable manufacturing process, device compatibility, and hospital economic evidence. An excipient change without a measurable clinical or operational benefit would likely command limited partnering value.

What revenue exposure does FOLOTYN create?

FOLOTYN’s revenue exposure is concentrated rather than broad. The product addresses a rare lymphoma population and is used after prior treatment failure. That limits patient volume but can support specialty-drug economics.

Revenue sensitivity is driven by:

• Number of eligible relapsed or refractory patients.
• Duration of treatment before toxicity or progression.
• Net price and payer restrictions.
• Hospital purchasing contracts.
• Vial waste.
• Availability of competing therapies.
• Generic timing.
• Supply continuity.

An improved presentation could protect revenue by lowering total treatment cost for providers without requiring a higher nominal price. The strongest commercial case would combine reduced preparation time, lower discarded drug, lower occupational exposure, and dependable refrigerated distribution.

Key Takeaways

• FOLOTYN contains a simple excipient system centered on sodium chloride, with hydrochloric acid and sodium hydroxide used for pH adjustment.
• The existing formulation offers limited intrinsic excipient-based differentiation.
• Orphan exclusivity from the 2009 approval period expired approximately in 2016.
• Generic competition is more likely to focus on a conventional equivalent injection than on a complex formulation challenge.
• Vial-size optimization, ready-to-administer packaging, low-sorption devices, and improved storage stability are the clearest commercial opportunities.
• A new formulation would need measurable stability, handling, safety, or economic advantages to justify 505(b)(2) development.
• The commercial moat is more likely to arise from manufacturing reliability, oncology distribution, workflow integration, and intellectual property around new presentations.
• Method-of-use and formulation patent value depends on current Orange Book listings and live patent records, not solely on the FDA product label.

FAQs

Can FOLOTYN be reformulated with a different buffer?

Yes, but the sponsor would need to demonstrate acceptable potency, impurity profile, pH, sterility, compatibility, and stability. A buffer change could also affect the FDA regulatory pathway and may prevent a straightforward ANDA approach.

Is a pralatrexate prefilled syringe commercially attractive?

Potentially. The strongest value proposition would be reduced pharmacy preparation, lower residual drug, and safer handling of a cytotoxic agent. The product would require robust container-closure, syringe-material, stability, and dose-recovery data.

Does FOLOTYN require a preservative?

The FDA label identifies FOLOTYN as a preservative-free injection. Adding a preservative would create compatibility, toxicity, labeling, and regulatory issues without an obvious commercial advantage for a single-dose oncology vial.

Could a generic use different excipients from FOLOTYN?

Potentially, provided the product satisfies FDA requirements for pharmaceutical equivalence, inactive-ingredient safety, stability, product quality, and therapeutic equivalence. A materially different formulation could require additional justification or a different approval pathway.

What is the best excipient-related investment thesis for FOLOTYN?

The strongest thesis is not a novel excipient by itself. It is a presentation strategy that combines a stable pralatrexate formulation with reduced vial waste, simpler oncology-pharmacy preparation, improved dose recovery, or more flexible storage.

References

1. U.S. Food and Drug Administration. (2023). FOLOTYN (pralatrexate injection) prescribing information. Acrotech Biopharma LLC.

2. U.S. Food and Drug Administration. (2009, September 24). FDA approves Folotyn for relapsed or refractory peripheral T-cell lymphoma. FDA.

3. Acrotech Biopharma LLC. (n.d.). FOLOTYN product information and company portfolio materials. Acrotech Biopharma.